Tech Transfer eNews Blog

Potentially groundbreaking brain injury treatment from U of Texas reaches clinical trials

By Jesse Schwartz
Published: June 22nd, 2022

Researchers have tested an experimental therapeutic developed at the University of Texas Health Science Center at San Antonio that could transform the treatment of stroke and traumatic brain injury (TBI) patients.

Known as AST-004, the drug is the result of a research collaboration between the lab of UT Health San Antonio professor James D. Lechleiter and private company Astrocyte Pharmaceuticals, which licensed the therapeutic in 2015 through the Office of Technology Commercialization.

The treatment was tested in the first human subject on June 14th as part of a clinical trial being conducted in Hungary. The trial is intended to evaluate the safety, tolerability and pharmacokinetic profile of AST-004.

“We started with preclinical experiments and next moved through a series of animal studies, beginning with mice and continuing in larger, more complex models,” says Lechleiter. “In each species, AST-004 protected the brain effectively and safely. Now, after these successes and approval by regulatory authorities, we have reached trials in humans. The science we delineated, and the results every step of the way, give us a measured confidence that this treatment will in the future be used in everyday life, including with mild concussions.”

Ted Liston, vice president of research at Astrocyte Pharmaceuticals, comments, “The collaboration with UT Health San Antonio has been sustained for almost eight years, and it has been a fantastic partnership. Our future plans are to continue to advance AST-004 and conduct clinical trials with patients in the U.S. and other countries, and then to seek approval of AST-004 from the U.S. Food and Drug Administration and other world regulatory agencies.”

Source: Yahoo! Finance

Posted under: Tech Transfer e-News